Market Overview

Jefferies Initiates Pfizer With Overweight

Related PFE
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Good Luck, AT&T! Here Are Recent Megamergers That Went Or Could Go Bust (Investor's Business Daily)

Analysts at Jefferies initiated coverage on Pfizer Inc. (NYSE: PFE) with a Overweight rating.

The target price for Pfizer is set to $45.

Pfizer shares have gained 14.57 percent over the past 52 weeks, while the S&P 500 index has surged 7.12 percent in the same period.

Pfizer shares rose 0.06 percent to close at $34.06 yesterday.

Latest Ratings for PFE

Oct 2016JefferiesDowngradesBuyHold
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesInitiation Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!